NRX Pharmaceuticals Appoints Dr. Javitt CEO, Chairman
Ticker: NRXPW · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $325,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, management
Related Tickers: NRXP
TL;DR
Javitt takes over as CEO/Chairman at NRX Pharma, replacing Smith.
AI Summary
NRX Pharmaceuticals, Inc. announced on November 18, 2024, the appointment of Dr. Jonathan Javitt as Chief Executive Officer and Chairman of the Board. Dr. Javitt previously served as the company's Chief Scientific Officer and has been instrumental in the development of NRX-101. The company also reported on the departure of its previous CEO and Chairman, Dr. Stephen R. Smith.
Why It Matters
This leadership change could signal a new strategic direction for NRX Pharmaceuticals, potentially impacting its drug development pipeline and market positioning.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategy and execution, impacting investor confidence.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan Javitt (person) — Appointed CEO and Chairman of the Board
- Dr. Stephen R. Smith (person) — Departing CEO and Chairman
- NRX-101 (drug) — Key development by Dr. Javitt
- November 18, 2024 (date) — Effective date of appointment
FAQ
Who has been appointed as the new CEO and Chairman of NRX Pharmaceuticals, Inc.?
Dr. Jonathan Javitt has been appointed as the new Chief Executive Officer and Chairman of the Board of NRX Pharmaceuticals, Inc.
What was Dr. Jonathan Javitt's previous role at NRX Pharmaceuticals?
Dr. Jonathan Javitt previously served as the Chief Scientific Officer of NRX Pharmaceuticals.
Who is departing from the CEO and Chairman roles?
Dr. Stephen R. Smith is departing from the CEO and Chairman roles.
What is the effective date of these leadership changes?
The changes were reported as of November 18, 2024.
What key development is Dr. Javitt associated with at NRX Pharmaceuticals?
Dr. Javitt has been instrumental in the development of NRX-101.
Filing Stats: 1,342 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2024-11-20 09:00:45
Key Financial Figures
- $0.001 — registered Common Stock , par value $0.001 pershare NRXP The Nasdaq Stock Marke
- $325,000 — lary (" Base Salary ") in the amount of $325,000, subject to an initial period rate of 5
Filing Documents
- nrxp20241120_8k.htm (8-K) — 36KB
- ex_750345.htm (EX-10.1) — 63KB
- ex_750346.htm (EX-99.1) — 13KB
- logo01.jpg (GRAPHIC) — 3KB
- 0001437749-24-035806.txt ( ) — 289KB
- nrxp-20241118.xsd (EX-101.SCH) — 4KB
- nrxp-20241118_def.xml (EX-101.DEF) — 13KB
- nrxp-20241118_lab.xml (EX-101.LAB) — 18KB
- nrxp-20241118_pre.xml (EX-101.PRE) — 14KB
- nrxp20241120_8k_htm.xml (XML) — 5KB
01
Item 1.01 Entry into a Material Definitive Agreement. The information set forth in Item 5.02 regarding the Employment Agreement, as defined below, is incorporated into this Item 1.01 by reference.
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 18, 2024, NRx Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company. Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company's financial function and other projects. Mr. Abrams, age 54, is a senior finance professional with experience serving as an executive officer, investment banker, director and senior advisor. Mr. Abrams has served as the Chief Financial Officer of Arch Therapeutics, Inc., a publicly traded biotechnology company, since May 2021, and is expected to continue in such capacity during the transition to his role as Chief Financial Officer of the Company. Mr. Abrams previously served as the Chief Financial Officer for RiseIT Solutions, Inc. from February 2019 to April 2021, where he helped return the business to profitability, and served as the Chief Financial Officer and as a director of FitLife Brands, Inc., a publicly traded entity focused on the development of functional nutritional supplements that promote an active, healthy lifestyle, from August 2009 to February 2019. Mr. Abrams earned his MBA with Honors from the Booth School of Business at the University of Chicago and received his BBA with Honors from the University of Massachusetts at Amherst as a William F. Field Alumni scholar. Pursuant to the terms of an employment agreement entered into on November 18, 2024 (the " Employment Agreement "), Mr. Abrams will serve as Chief Financial Officer of the Company for a one-year term, which term shall be automatically extended thereafter for successive one-year terms, until terminated in accordance with the terms of the Employment Agreement. The Employment Agreement provides that Mr. Abrams will receive an annual base salary ("
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Employment Agreement between Michael Abrams and NRx Pharmaceuticals, Inc., dated November 18, 2024 99.1 Press Release, dated November 18, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: November 20, 2024 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer